S2 Episode 4: Cardiovascular Risk in Patients With Psoriatic Arthritis

Drs Stanley Cohen and Atul Deodhar discuss cardiovascular risk in patients with psoriatic arthritis and the impact of effective treatment.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970784). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results From the CARMA Cohort https://journals.lww.com/jclinrheum/Abstract/2022/03000/Prevalence_of_Metabolic_Syndrome_in_Psoriatic.22.aspx

Metabolic Syndrome https://emedicine.medscape.com/article/165124-overview

What Is the Framingham Risk Score (FRS)? https://www.medscape.com/answers/2500032-166149/what-is-the-framingham-risk-score-frs

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines https://www.sciencedirect.com/science/article/pii/S0735109713060312?via%3Dihub

What Is the Systematic Coronary Risk Evaluation (SCORE)? https://www.medscape.com/answers/2500032-166154/what-is-the-systematic-coronary-risk-evaluation-score

Anti-inflammatory Therapy With Canakinumab for Atherosclerotic Disease https://www.nejm.org/doi/pdf/10.1056/nejmoa1707914

Colchicine in Patients With Chronic Coronary Disease https://www.nejm.org/doi/10.1056/NEJMoa2021372

The Effects of Tumour Necrosis Factor Inhibitors, Methotrexate, Non-steroidal Anti-inflammatory Drugs and Corticosteroids on Cardiovascular Events in Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis https://ard.bmj.com/content/74/3/480

Psoriatic Arthritis Medication https://emedicine.medscape.com/article/2196539-medication

Efficacy and Safety of Selective TYK2 Inhibitor, Deucravacitinib, in a Phase II Trial in Psoriatic Arthritis https://ard.bmj.com/content/81/6/815

FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death